Latest Cilomilast Stories
New research report “COPD Drug Market Opportunity & Clinical Pipeline Analysis” worked out by Kuick Research is now available at MarketPublishers.com.
Physician organizations are announcing new recommendations to consider when diagnosing and treating COPD.
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but does not increase general quality of life.
Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD).
PHILADELPHIA, Sept. 25 /PRNewswire/ -- Patients at risk of coronary disease who have reactive airways may breathe easier thanks to new data released today at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology.
Mpex Pharmaceuticals, a clinical stage biopharmaceutical company, has initiated a Phase II clinical study with MP-376 for use as a maintenance therapy in reducing the incidence of pulmonary exacerbations in patients with chronic obstructive pulmonary disease.
REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA).
Osiris Therapeutics, a stem cell therapeutic company, has completed enrollment in a human clinical trial designed to evaluate Prochymal, the company's proprietary formulation of adult mesenchymal stem cells, for the treatment of moderate to severe chronic obstructive pulmonary disease.
Dynavax Technologies, Inc. (NASDAQ:DVAX) today announced receipt of a $4.5 million milestone payment from its partner AstraZeneca AB for the nomination of candidate drug AZD1419 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
NEW YORK, Sept. 3 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. and Laboratorios Almirall, S.A.
- A serpent whose bite was fabled to produce intense thirst.